Dr. Moroose is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Orlando Health Cancer Institute
1414 Kuhl Ave
Orlando, FL 32806
Education & Training
- University of ConnecticutFellowship, Hematology and Medical Oncology, 1983 - 1986
- University of ConnecticutResidency, Internal Medicine, 1981 - 1983
- University of MarylandInternship, Internal Medicine, 1980 - 1981
- Uconn School Of MedicineClass of 1980
Certifications & Licensure
- FL State Medical License 1986 - 2025
- American Board of Internal Medicine Internal Medicine
Clinical Trials
- Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery Start of enrollment: 2009 Apr 01
- A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Start of enrollment: 2013 Oct 14
- Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. Start of enrollment: 2015 Jun 09
- Join now to see all
Publications & Presentations
PubMed
- 36 citationsRationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapyendocrine therapy alone in patients with HR+/HER2- early breast cancer.Dennis J Slamon, Peter A Fasching, Sara Hurvitz, Stephen Chia, John Crown
Therapeutic Advances in Medical Oncology. 2023-01-01 - 5 citationsEvaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment.Cen Guo, Yanke Yu, Jayeta Chakrabarti, Sarina A Piha-Paul, Rebecca Moroose
British Journal of Clinical Pharmacology. 2022-07-01 - 3 citationsChaperonin containing TCP1 as a marker for identification of circulating tumor cells in blood.Amanda Cox, Ana Martini, Heba Ghozlan, Rebecca Moroose, Xiang Zhu
Plos One. 2022-01-01
Press Mentions
- The Importance of Testing for Breast CancerDecember 11th, 2021
- Breast Cancer: What Every Woman Should KnowDecember 1st, 2021
- When Breast Cancer Strikes Under 40October 12th, 2016
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: